# Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects

> **NCT02208856** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBR 796 BS
- **DRUG:** Placebo
- **OTHER:** high fat standardized breakfast

## Key facts

- **NCT ID:** NCT02208856
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 1999-12
- **Final completion:** —
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02208856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02208856, "Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02208856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*